Transcatheter aortic valve implantation (TAVR) has transformed treatment for high-risk aortic stenosis patients, but its recent use in low-risk younger populations and those with bicuspid aortic valves (BAV) raises concerns about valve durability and increased mortality and stroke rates. Emerging data suggests that TAVR risks may accumulate over time, particularly in patients with BAV. This article highlights the need for further research to inform clinical decisions regarding TAVR in younger patients.